腾博会官网·[中国]-诚信为本,专业服务!

VOLUNTARY ANNOUNCEMENT INNOVATIVE DRUG "TQ-B3525" WAS INCLUDED IN THE LIST OF BREAKTHROUGH THERAPY DRUGS BY CDE

NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF CATEGORY I NEW DRUG "TQC2938" INJECTION

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2022

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER, 2021

SHARE PURCHASE PLAN

FINAL DIVIDEND FOR 2021

VOLUNTARY ANNOUNCEMENT CATEGORY I ANTI-TUMOUR INNOVATIVE MEDICINE FHND5071 OBTAINED APPROVAL FOR CLINICAL TRIAL